Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com
by Renee Jackson · The Cerbat GemStockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note released on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.
Separately, Maxim Group raised shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 target price for the company in a report on Thursday, July 11th.
Read Our Latest Report on BCLI
Brainstorm Cell Therapeutics Price Performance
Shares of BCLI stock opened at $2.33 on Tuesday. The company has a market cap of $163.29 million, a price-to-earnings ratio of -6.94 and a beta of 0.33. Brainstorm Cell Therapeutics has a 1 year low of $2.01 and a 1 year high of $11.89. The firm has a fifty day moving average price of $0.44 and a 200-day moving average price of $0.46.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). During the same period in the prior year, the business posted ($0.27) EPS. Equities research analysts expect that Brainstorm Cell Therapeutics will post -0.19 EPS for the current year.
Hedge Funds Weigh In On Brainstorm Cell Therapeutics
An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 14.33% of the company’s stock.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Recommended Stories
- Five stocks we like better than Brainstorm Cell Therapeutics
- What is the Hang Seng index?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- Investing in the High PE Growth Stocks
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- What is MarketRank™? How to Use it
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally